Wire · opportunities
Lilly wins FDA approval for Inluriyo-Verzenio breast cancer combo
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 September 2026 · Fusion42 review
The US FDA granted full approval to Lilly's oral combination of Inluriyo (imlunestrant) and Verzenio (abemaciclib) for adults with ER+, HER2–, ESR1-mutated advanced or metastatic breast cancer after progression on endocrine therapy, based on Phase III trial data showing doubled progression-free survival.
This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 18 Sep 2026 and 21 Sep 2026.
◆ ◆ The Wire takeaway
You have a new orally administered breast cancer therapy approved for ESR1-mutated cases post-endocrine therapy. Quickly consider how this expands treatment sequencing options and outflanks competitors with intravenous regimens.
◆ Coverage
5 sources · first reported 18 Sep 2026 · latest 21 Sep 2026
◆ Related on Wire
◆ Topics